Cleaved-MMP14 (Y112) Antibody

What is the difference between total MMP14 and Cleaved-MMP14 (Y112)?

MMP14 is produced as an inactive zymogen and undergoes processing to generate active forms. The full-length MMP14 (also known as MT1-MMP) is approximately 65-66 kDa, while the cleaved form at Y112 represents a specific activation state resulting in a 53 kDa protein. Anti-Cleaved-MMP14 (Y112) antibodies specifically recognize the cleaved form, allowing researchers to distinguish between inactive pro-MMP14 and the activated form . This distinction is crucial for studies investigating MMP14 activation during various physiological and pathological processes.

How are Cleaved-MMP14 (Y112) antibodies validated for specificity?

Validation typically involves multiple approaches:

• Western blot analysis using positive controls such as human placenta tissue, rat spleen tissue, HELA whole cell lysate, and A549 whole cell lysate

• Comparative analysis of pro-MMP-14 (65 kDa) versus Cleaved-MMP-14 (53 kDa) bands

• Peptide competition assays using immunogen peptides

• Knockout/knockdown validation in cell lines using CRISPR-Cas9 or siRNA approaches

• Cross-reactivity testing with other MMP family members

What is the significance of Y112 as a cleavage site in MMP14?

The Y112 cleavage site is located within the catalytic domain of MMP14 and represents a specific processing event distinct from the furin cleavage that activates the pro-enzyme. This cleavage generates a fragment that retains the catalytic domain but has altered biological properties compared to the full-length enzyme. The cleaved form has been implicated in various signaling pathways and may have distinct substrate specificities . The region around this cleavage site (approximately 93-142 amino acids) contains important structural elements that affect MMP14 function.

What are the optimal protocols for detecting Cleaved-MMP14 (Y112) via Western blotting?

For optimal Western blot detection:

Recommended protocol:

• Sample preparation: Use RIPA buffer with protease inhibitors

• Loading: 40-50 μg of protein per lane

• Gel concentration: 10-12% SDS-PAGE

• Transfer: PVDF membrane (0.45 μm pore size)

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour

• Primary antibody: Dilute anti-Cleaved-MMP14 (Y112) at 1:500-1:2000 in blocking buffer

• Incubation: Overnight at 4°C

• Secondary antibody: Anti-rabbit HRP at 1:5000-1:10000

• Detection: ECL substrate with 1-5 minute exposure

Expected results: Cleaved-MMP14 (Y112) should appear at approximately 53 kDa, while the pro-form may be visible at 65 kDa .

How can researchers optimize immunohistochemistry protocols for Cleaved-MMP14 (Y112) detection in tissue sections?

Although most Cleaved-MMP14 (Y112) antibodies are primarily validated for Western blotting, IHC optimization can be achieved by:

• Fixation: 4% paraformaldehyde is preferred; formalin fixation may mask epitopes

• Antigen retrieval: Citrate buffer (pH 6.0) with heat-induced epitope retrieval

• Blocking: 5-10% normal serum corresponding to secondary antibody species

• Primary antibody concentration: Start with 0.5-1 μg/ml

• Incubation: Overnight at 4°C in a humidified chamber

• Controls: Include human intestinal cancer tissue, human placenta tissue, or rat cardiac muscle tissue as positive controls

• Detection: Use polymer-based detection systems for enhanced sensitivity

What methodological approaches can overcome inconsistent results when using Cleaved-MMP14 (Y112) antibodies?

Inconsistent results can be addressed through:

• Fresh antibody preparation: Avoid repeated freeze-thaw cycles

• Optimized sample preparation: Include phosphatase inhibitors along with protease inhibitors

• Tissue-specific validation: Different tissues may require different retrieval methods

• Recombinant protein controls: Include recombinant MMP14 fragments (112-582aa region) as positive controls

• Cross-validation: Compare results using different detection methods (Western blot, ELISA, IHC)

• Carrier protein consideration: Some applications may require BSA-free formulations

• Batch consistency: Monitor lot-to-lot variations by maintaining reference samples

How can Cleaved-MMP14 (Y112) antibodies be used to investigate circadian regulation of MMP14?

Research has shown that MMP14 expression exhibits circadian rhythmicity in tissues like tendon . Experimental design should include:

• Time-course collection: Harvest samples at multiple time points throughout a 24-hour cycle

• Synchronized cell systems: Use dexamethasone, serum shock, or forskolin to synchronize cellular clocks

• Parallel analysis: Compare Cleaved-MMP14 (Y112) levels with MMP14 mRNA expression

• Clock gene manipulations: Examine Cleaved-MMP14 (Y112) levels in CLOCK mutant or BMAL1 knockout models

• Quantification method: Use densitometry of Western blots normalized to housekeeping proteins

• Circadian markers: Include parallel measurements of established circadian proteins (PER2, BMAL1)

Time-series Western blot analysis has shown peak levels of MT1-MMP at CT3 (3 hours after the circadian transition), approximately 4 hours after the peak in transcript levels .

What experimental approaches can determine if Cleaved-MMP14 (Y112) has distinct biological functions compared to full-length MMP14?

To distinguish the functions:

• Domain-specific constructs: Generate expression constructs lacking specific domains (catalytic, hemopexin, transmembrane)

• Site-directed mutagenesis: Create Y112F mutants to prevent cleavage

• Rescue experiments: Reintroduce wild-type or mutant MMP14 into knockout cells

• Cleavage-specific inhibitors: Develop compounds that specifically prevent Y112 cleavage

• Proteomics approaches: Compare substrate profiles of full-length versus cleaved forms

• Cell-based assays: Compare migration, invasion, and matrix remodeling capacities

• In vivo models: Generate knock-in mice expressing cleavage-resistant MMP14

Research has demonstrated that the transmembrane/cytoplasmic domains of MMP14, rather than just its catalytic activity, are crucial for functions like mammary epithelial cell invasion and branching .

How can researchers investigate the relationship between Cleaved-MMP14 (Y112) and integrin β1 signaling?

Based on the literature showing direct interaction between MMP14 and integrin β1 , experimental approaches should include:

• Co-immunoprecipitation: Using anti-Cleaved-MMP14 (Y112) antibodies to pull down complexes

• Proximity ligation assays: Visualize interactions in situ

• FRET imaging: Monitor direct molecular interactions using fluorescent tags

• Domain mapping: Identify specific domains required for the interaction

• Phosphorylation analysis: Examine how cleaved MMP14 affects integrin signaling pathways

• Functional assays: Measure effects on cell adhesion, migration, and matrix invasion

• Inhibitor studies: Use specific inhibitors of both pathways to delineate dependencies

FRET analysis has confirmed physical interaction between MMP14 and integrin β1, explaining how MMP14 can activate MAPK signaling despite lacking a kinase domain .

How can Cleaved-MMP14 (Y112) antibodies be utilized to investigate cancer invasion and metastasis mechanisms?

Experimental design should include:

• Human tissue arrays: Compare cleaved MMP14 levels across tumor stages and grades

• 3D invasion assays: Examine the effects of MMP14 cleavage on invasion through different matrices

• Live cell imaging: Track MMP14 trafficking and localization during invasion

• In vivo models: Analyze cleaved MMP14 in experimental metastasis models

• Patient-derived xenografts: Evaluate therapeutic targeting potential

• Correlation studies: Relate cleaved MMP14 levels to clinical outcomes

• Combination studies: Examine synergy with other pro-metastatic factors

Research has demonstrated that MMP14 is upregulated in several cancer types and promotes angiogenesis, inflammation, cancer cell invasion, and metastasis .

What methodological approaches can distinguish between autocatalytic and non-autocatalytic cleavage of MMP14?

Distinguishing between different cleavage mechanisms requires:

• In vitro cleavage assays: Recombinant MMP14 with catalytic site mutations

• Mass spectrometry: Identify precise cleavage sites and resulting fragments

• Selective inhibitors: Use MMP inhibitors with different specificities

• Time-course analysis: Monitor the kinetics of different cleaved forms

• Immunoprecipitation: Isolate specific cleaved forms for further analysis

• Zymography: Assess enzymatic activity of different cleaved forms

• Domain-specific antibodies: Use antibodies recognizing different regions

Research has identified that MMP14 can undergo autocatalytic cleavage in the hinge region to generate a 44-kDa inactive form, as well as non-autocatalytic shedding that produces a 50-kDa enzymatically active fragment .

How can researchers differentiate between specific and non-specific bands when using Cleaved-MMP14 (Y112) antibodies?

To ensure specificity:

• Multiple antibody approach: Use antibodies from different manufacturers or targeting different epitopes

• Blocking peptide controls: Pre-incubate antibody with immunizing peptide

• Knockout/knockdown validation: Compare with MMP14-depleted samples

• Recombinant protein standards: Include purified MMP14 fragments

• Molecular weight verification: Cleaved-MMP14 (Y112) should appear at approximately 53 kDa

• Treatment controls: Include samples treated with MMP inhibitors

• Cross-reactivity testing: Check against other MMP family members

When using Western blotting, validated antibodies typically detect Pro-MMP-14 at 65 kDa and Cleaved-MMP-14 at 53 kDa .

What are the critical factors affecting the stability and storage of Cleaved-MMP14 (Y112) antibodies?

For optimal antibody performance:

• Storage temperature: -20°C for long-term storage (up to one year)

• Short-term storage: 4°C for up to one month for frequent use

• Avoid freeze-thaw cycles: Aliquot antibodies before freezing

• Buffer composition: PBS with 50% glycerol and 0.02% sodium azide provides stability

• BSA content: 0.5% BSA helps prevent non-specific binding

• Working dilution: Prepare fresh dilutions for each experiment

• Temperature sensitivity: Avoid exposure to high temperatures during shipping or handling

As specified in product information, some antibodies may be provided in lyophilized form and require reconstitution before use .

How can researchers resolve discrepancies between tissue-specific expression patterns of Cleaved-MMP14 (Y112)?

To address tissue-specific variations:

• Comprehensive literature review: Compare expression data across published studies

• Multiple detection methods: Use complementary techniques (WB, IHC, IF, qPCR)

• Tissue processing optimization: Adjust fixation and retrieval methods for each tissue type

• Multiple antibody validation: Test several antibodies targeting different epitopes

• Specificity controls: Include tissues known to be positive or negative for MMP14

• Species considerations: Verify sequence homology when comparing across species

• Developmental timing: Consider age-dependent expression patterns

According to literature, MMP14 is expressed in diverse tissues including endocervix, placenta, lung, tongue, skin, and melanoma, with expression patterns that may vary by developmental stage or physiological conditions .

How can Cleaved-MMP14 (Y112) antibodies contribute to investigating non-proteolytic functions of MMP14?

Experimental approaches should include:

• Catalytic-dead mutants: Compare with wild-type MMP14 in functional assays

• Protein-protein interaction studies: Identify binding partners specific to cleaved forms

• Signal transduction analysis: Examine effects on intracellular signaling pathways

• Subcellular localization studies: Track trafficking and compartmentalization

• Functional rescue experiments: Test domain-specific constructs in knockout cells

• Transcriptional profiling: Identify genes regulated by non-proteolytic activities

• In vivo modeling: Generate transgenic models expressing cleaved forms

Research has revealed that MMP14 can regulate signaling pathways and cell behaviors independently of its catalytic activity, particularly through its transmembrane and cytoplasmic domains .

What methodological approaches can investigate the role of Cleaved-MMP14 (Y112) in extracellular matrix homeostasis?

To study ECM interactions:

• 3D matrix models: Use defined collagen matrices of varying densities

• Fibril assembly assays: Monitor collagen fibrillogenesis in the presence of cleaved MMP14

• Electron microscopy: Examine ultrastructural changes in ECM organization

• Biomechanical testing: Measure matrix stiffness and viscoelastic properties

• Live imaging: Track ECM remodeling in real-time

• Proximity proteomics: Identify ECM components interacting with cleaved MMP14

• Mass spectrometry: Identify specific cleavage sites in ECM proteins

Studies have shown that MMP14 plays a crucial role in collagen turnover and bone remodeling, with knockout mice exhibiting defects in skeletal development, angiogenesis, and fibrosis of soft tissues .